MedPath

Kelun-Biotech's SKB571 Receives Green Light for Clinical Trials

• Sichuan Kelun-Biotech has received approval to proceed with clinical trials for its investigational drug, SKB571. • SKB571 represents a novel therapeutic approach, though specific details regarding its mechanism of action and target indications remain undisclosed. • The approval marks a significant milestone for Kelun-Biotech, potentially expanding its pipeline of innovative pharmaceutical products. • Further details regarding the trial design, patient population, and clinical endpoints are anticipated to be released as the study progresses.

Sichuan Kelun-Biotech has announced the approval to commence clinical trials for its drug candidate, SKB571. This regulatory milestone allows the company to advance the development of this investigational agent, though details regarding the specific indications and mechanisms of action have not been disclosed in the initial announcement. The commencement of these trials represents a significant step for Kelun-Biotech in expanding its portfolio of pharmaceutical products.
While specific details regarding the trial design, patient population, and clinical endpoints are currently unavailable, the initiation of clinical trials suggests that SKB571 has demonstrated sufficient preclinical promise to warrant further investigation in human subjects. The company is expected to release further information as the trials progress.
The approval for SKB571 trials underscores Kelun-Biotech's commitment to innovation in the pharmaceutical sector. Further updates will be provided as they become available.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CEL-SCI's Multikine Demonstrates Promising Tumor Regression, Advances to Confirmatory Phase 3 Trial for Head and Neck Cancer

CEL-SCI's Multikine showed significant pre-surgical tumor regression in head and neck cancer patients within three weeks, a finding confirmed by pathology.
The FDA has approved CEL-SCI's plan to use PD-L1 as a biomarker for patient selection in the confirmatory Phase 3 trial, focusing on patients with low PD-L1 expression.

Kelun-Biotech Announces Exclusive License Agreement for SKB378/HBM9378, an Anti-TSLP Monoclonal Antibody

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has entered into an exclusive license agreement with Windward Bio AG for SKB378/HBM9378, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody. The agreement grants Windward Bio exclusive rights for the research, development, manufacturing, and commercialization of SKB378/HBM9378 globally, excluding Greater China and several Southeast and West Asian countries. Kelun-Biotech and Harbour BioMed, the co-developers, are eligible to receive up to US$970 million in payments and royalties.

Kelun-Biotech's SKB571 Receives Green Light for Clinical Trials in Solid Tumors

Sichuan Kelun-Biotech has been granted approval to commence clinical trials for SKB571, a novel drug targeting solid tumors, including lung and gastrointestinal cancers.
The company secured a $37.5 million payment from Merck & Co., with potential for future milestone payments and royalties, indicating significant industry interest.

Kelun-Biotech's SKB535 Receives Approval for Clinical Trials in Advanced Solid Tumors

Kelun-Biotech's SKB535, an innovative antibody-drug conjugate (ADC), has been approved by China's NMPA for clinical trials targeting advanced solid tumors.
The drug was developed using Kelun-Biotech’s OptiDC platform and has demonstrated promising preclinical results, warranting further clinical investigation.

Kelun-Biotech's SKB445 ADC Receives NMPA Approval for Advanced Solid Tumor Trials

Kelun-Biotech's SKB445, a novel antibody-drug conjugate (ADC), has been approved by China's NMPA for clinical trials in advanced solid tumors.
SKB445 leverages Kelun-Biotech's OptiDC platform, demonstrating promising preclinical efficacy and a favorable safety profile.

Pimicotinib Shows Positive Phase 3 Results in Tenosynovial Giant Cell Tumors

Pimicotinib demonstrated a 54% objective response rate at week 25, significantly higher than the 3.2% observed in the placebo group in TGCT patients.
The MANEUVER trial confirmed pimicotinib's potential as a new treatment option by showing statistically significant improvements in patient outcomes, including reduced stiffness and pain.

Pimicotinib Achieves Primary Endpoint in Phase 3 Trial for Tenosynovial Giant Cell Tumor

Merck KGaA's pimicotinib demonstrated a significant objective response rate (ORR) of 54% at week 25 compared to 3.2% for placebo in the MANEUVER trial.
The CSF-1R inhibitor showed efficacy in reducing joint stiffness and pain, as measured by NRS and BPI pain scores, respectively.

Sacituzumab Tirumotecan (Sac-TMT) Approved in China for Advanced TNBC

Kelun-Biotech's Sacituzumab tirumotecan (Sac-TMT) has received marketing approval in China for treating advanced or metastatic triple-negative breast cancer (TNBC).
The approval is based on the Phase III OptiTROP-Breast01 trial, which showed Sac-TMT significantly improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy.

Merck Finalizes Acquisition of Curon Bio's Bispecific Antibody CN201 for B-Cell Malignancies

Merck has completed its acquisition of CN201, a bispecific antibody from Curon Biopharmaceutical, aimed at treating relapsed or refractory non-Hodgkin lymphoma and B-cell acute lymphocytic leukemia.
Early Phase I trial data indicates CN201 is well-tolerated and effectively reduces B-cell populations, showing potential for sustained clinical benefits in patients with B-cell malignancies.

CEL-SCI Receives FDA Approval for Confirmatory Study of Multikine in Head and Neck Cancer Treatment

CEL-SCI Corporation has received FDA approval to proceed with a confirmatory study of its cancer immunotherapy, Multikine, for newly diagnosed advanced primary head and neck cancer patients. The study, based on strong safety and efficacy data from a completed Phase 3 study, aims to confirm the survival benefits observed in the target patient population.

Reference News

[1]
Sichuan Kelun-Biotech Gains Approval for SKB571 Trials - TipRanks.com
tipranks.com · Nov 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HK:6990) received approval for clinical trials of novel drug SKB571 t...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy